Daniel Anton de Boer, Director, Chief Executive Officer, on July 31, 2026, executed a purchase for 200,000 shares in Proqr Therapeutics (PRQR) for $353,960. Following the Form 4 filing with the SEC, de Boer has control over a total of 500,000 ordinary shares of the company, with 500,000 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1612940/000110465926089780/xslF345X05/tm2622051-1_4seq1.xml